serotonin 2A receptor
A specific subtype of serotonin receptor, heavily expressed in the cortex, whose stimulation is the shared pharmacological mechanism of all classic psychedelics.
As defined in 82 | Robin Carhart-Harris on Psychedelics and the Brain
Where it comes up · 5
- 82 | Robin Carhart-Harris on Psychedelics and the Brain5 claims
- 478 - The Psychedelic Mind1 claim
- 306 - Psychedelics Mortality1 claim
- 337 - The Future Of Psychedelic Medicine1 claim
- 177 - Psychedelic Science1 claim
Most important claims · 9 of 9Search all claims for “serotonin 2A receptor” →
- The serotonin 2A receptor is heavily expressed in the cortex—evolutionarily recent and massively expanded in humans—and is especially concentrated in the association cortex at the top of the brain's hierarchy, which underlies high-level functions like imagination, counterfactual thinking, and self-consciousness.82 | Robin Carhart-Harris on Psychedelics and the Brain
- The entropic brain principle holds that psychedelics increase the unpredictability (entropy) of spontaneous brain activity, producing richer ongoing consciousness; there is a reliable relationship between the richness of conscious content and the entropy of brain activity.82 | Robin Carhart-Harris on Psychedelics and the Brain
- Serotonin is not a simple excitatory or inhibitory signal but a complex neuromodulator that tunes neural function, reflected in its at least 14 sub-receptors that do different things, some opposing each other; the 2A receptor specifically is excitatory and increases an irregular form of excitation.82 | Robin Carhart-Harris on Psychedelics and the Brain
- The scientifically crisp definition of a classic psychedelic is pharmacological: LSD, psilocybin, DMT, and mescaline all share the property of stimulating the serotonin 2A receptor, which distinguishes them from loosely 'psychedelic' drugs like cannabis or MDMA.82 | Robin Carhart-Harris on Psychedelics and the Brain
- Stimulating the serotonin 2A receptor is the key initiation site for classic psychedelics, evidenced by a tight positive correlation between a psychedelic's binding affinity for that receptor and its potency, by the fact that pre-treatment with a 2A antagonist blocks the trip, and by the ability to abort a trip by administering the blocker afterward.337 - The Future Of Psychedelic Medicine
- All classic psychedelics (psilocybin, LSD, mescaline, DMT) share a primary site of action at the serotonin 2A receptor, and the interesting effects they produce are mediated through that receptor's signaling pathway, as demonstrated by antagonist studies, serotonin 2A knockout mice, and human blocking studies; they differ in onset, duration, and secondary receptor targets (LSD being the most pharmacologically complex), but are more similar than different.177 - Psychedelic Science
- The classic psychedelics all bind the serotonin 2A receptor and produce broadly similar acute effects pharmacologically, yet experientially they differ substantially—LSD is similar to but way different from psilocybin, which differs from mescaline, which differs from DMT—leaving much interesting work to be done characterizing those differences.306 - Psychedelics Mortality
- Because blocking the 2A receptor has only subtle baseline effects, Carhart-Harris hypothesizes the serotonin 2A system functions as a 'crisis button' that becomes naturally engaged during exceptional conditions of existential distress, inducing hyper-plastic brain and mind states that enable transformative change—analogous to religious epiphanies or hitting rock bottom.82 | Robin Carhart-Harris on Psychedelics and the Brain
- Correcting the popularized 2012 myth that psychedelics simply reduce default mode network activity, the more accurate picture is that classic psychedelics dysregulate the DMN by binding to heavily-expressed serotonin 2A receptors there and causing irregular excitation—increased entropy moving the system from order toward disorder, analogous to temperature jiggling molecular organization toward a state transition.478 - The Psychedelic Mind